Ligand Pharmaceuticals: Q3 Earnings Insights

Ligand Pharmaceuticals LGND reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:01 PM.

Here's what investors need to know about the announcement.

Ligand Pharmaceuticals beat estimated earnings by 67.21%, reporting an EPS of $1.02 versus an estimate of $0.61.

Revenue was down $33.22 million from the same period last year.

Last quarter the company beat on EPS by $0.78 which was followed by a 5.35% increase in the share price the next day.

Here's a look at Ligand Pharmaceuticals's past performance:

Quarter	Q2 2023	Q1 2023	Q4 2022	Q3 2022
EPS Estimate	0.64	0.89	1.19	0.43
EPS Actual	1.42	2.28	1.36	1.31
Revenue Estimate	25.73M	34.04M	46.64M	38.28M
Revenue Actual	26.37M	43.98M	50.38M	66.09M

To track all earnings releases for Ligand Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.